Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 16/20 | 0.58 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1410227 | 0.85 | NOTUM (0.66) | NOTUMDPP4 | |
| SCHEMBL1410170 | 0.81 | DPP4 (0.47) | NOTUMDPP4 | |
| SCHEMBL1410375 | 0.80 | KDM4E (0.44) | NOTUMTSHR | |
| SCHEMBL29141957 | 0.79 | NOTUM (0.69) | NOTUMDPP4 | |
| SCHEMBL1409534 | 0.73 | NOTUM (0.65) | NOTUM | |
| SCHEMBL12809875 | 0.72 | NOTUM (0.49) | NOTUM | |
| SCHEMBL1409621 | 0.72 | NOTUM (0.68) | NOTUMDPP4 | |
| SCHEMBL12210031 | 0.72 | NOTUM (0.65) | NOTUMDPP4 | |
| SCHEMBL25216959 | 0.72 | MAPT (0.63) | NOTUMDPP4TSHRMAPK1 | |
| SCHEMBL28234009 | 0.71 | NOTUM (0.67) | NOTUMDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2295406-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-04-23 | — | — | EP | disclosed |
| US-8338622-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-12-25 | — | — | US | disclosed |
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2295406-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-03-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251187-A1 | HETEROCYCLIC COMPOUND | NES, BMI1, DOT1L | NOTUM 874/4885DPP4 1356/4885TSHR 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.